October 2025 CLL Bloodline
September 30, 2025
October 2025 CLL Bloodline: Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
October 2025 CLL Bloodline: Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
September 2025 CLL Bloodline: Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL. It will also provide news, help with the acronyms and new vocabulary words, and offer simple fun quizzes. The cycle restarts and it is updated annually.
MRD guided venetoclax based therapy can lead to durable remissions in both the frontline and relapsed/refractory (R/R) setting in CLL
Serious infections are a key issue in CLL. Real-world data show they occur significantly less with zanubrutinib than with venetoclax and obinutuzumab.
Access important medications in the CLL Society Clinician Medicine Cabinet. Download key resources and order a Welcome Kit.
Infections are the leading cause of death in chronic lymphocytic leukemia (CLL). My epcoritamab trial has put me at risk.
The risk of dangerous tumor lysis syndrome, when venetoclax is started, has limited its use in the community.
The EU commission has approved acalabrutinib in combination with venetoclax, with or without obinutuzumab, for the frontline treatment of CLL.
June 2025 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.